News

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

Irina Mazur spoke to Dermatology Times about the latest partnership, which aims to bridge the gap between clinical advice and patient behavior through personalized sun protection guidance.

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

The FDA warned Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.

Discover how the NEA Seal of Acceptance helps clinicians recommend safe eczema products, ensuring quality and sensitivity for patients with atopic dermatitis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

Shannon C. Trotter, DO, FAOCD, FAAD, and patient Janene Tirado, highlight GPP Awareness Day and the urgent need for recognition and understanding of generalized pustular psoriasis.

TikTok's vitiligo content reveals a critical need for reliable clinical information from HCPs, highlighting the gap between engagement and accuracy in health education.

Merck's pembrolizumab gains Health Canada approval for innovative perioperative treatment of advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Vitiligo significantly influences patients' quality of life, affecting major life decisions and increasing perceived stigma.

Explore personalized systemic therapies for atopic dermatitis, addressing patient needs, treatment options, and enhancing adherence for better outcomes.

This review of the latest dermatologic studies includes findings on cybersecurity practices in dermatology, compression therapy for cellulitis, melanoma overdiagnosis, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

New 76-week data reveals guselkumab's significant benefits for plaque psoriasis, enhancing clinical outcomes, improving quality of life, and reducing stigmatization.

New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.

Explore the evolving landscape of moderate psoriasis treatment, emphasizing patient-centered care and innovative therapies for improved quality of life.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

IKI Skin Care by Maria Urbani, MD offers effective solutions for rosacea and sensitive skin through science-backed, minimalist formulations.

Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Explore the latest advancements in psoriasis treatment, including pediatric care and innovative therapies, during Psoriasis Action Month. Stay informed!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

In case you missed it, this week we had news about a novel PDE4 inhibitor for plaque psoriasis, the evolution of 5-ALA, a new melanoma treatment plan combining vidutolimod with pembrolizumab, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.

Robert Koppel, MD, led Case-Based Roundtable attendees through 3 complex cases of atopic dermatitis that centered around available non-steroidal topicals and biologics.